# CagriSema vs Amycretin: How They Differ | PepVault

Source: https://pepvault.app/peptides/compare/cagrisema-vs-amycretin

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) CagriSema vs Amycretin

Compared side by side

# CagriSema vs amycretin: how they differ

Reviewed November 2026 [How we check the library](https://pepvault.app/about#library) [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The short answer

Both give the GLP-1 and the amylin signal: CagriSema as two weekly drugs, semaglutide and cagrilintide, and amycretin as one Novo Nordisk peptide that switches on both receptors, as a weekly shot or a daily tablet. Neither is approved: Novo Nordisk filed CagriSema with the FDA in December 2025, and amycretin, now named zenagamtide, has been in phase 3 since February 2026. In its main trial CagriSema averaged about 20% weight loss at 68 weeks, and in a small phase 1b/2a trial weekly amycretin shots took off about 22% at 20 mg and 24% at 60 mg over 36 weeks.

## Side by side

| Compared | [CagriSema](https://pepvault.app/peptides/cagrisema) | [Amycretin](https://pepvault.app/peptides/amycretin) |
| --- | --- | --- |
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Cagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + Sema | Zenagamtide, NNC0487-0111, Amy |
| What it is | Two weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic. | One peptide from Novo Nordisk that gives both the GLP-1 and the amylin signal, the pair CagriSema delivers as two drugs, as a weekly shot or a daily tablet. |
| How it works | Weekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026. | One peptide that switches on both the GLP-1 receptor and the amylin receptors (and the calcitonin receptor), so it carries the two signals CagriSema gives as two drugs. GLP-1 curbs appetite and slows the stomach; amylin adds fullness after meals. A fatty-acid side chain binds it to albumin in the blood, so a weekly shot lasts. Novo Nordisk is developing it as a weekly injection and as a daily tablet. Investigational, in phase 3 since February 2026. |
| Commonly reported | Strong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet. | In trials, strong appetite loss and GI side effects during the step-ups. Now named zenagamtide; in phase 3 and not approved anywhere. |
| Studied range | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. | Research range: 0.4–60 mg, starting dose 0.2 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial) | ~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | Studied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025. | Used continuously, once weekly, in its trials: up to 36 weeks so far, with doses stepped up every 4 weeks. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, vomiting, diarrhea, constipation, abdominal pain | Nausea, vomiting, diarrhea, decreased appetite |

Typical run: Community practice — opinions vary. Not a clinical recommendation.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking CagriSema or amycretin? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### CagriSema

- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg of each
- Day 57–364 · 1 mg 1 mg of each, halfway up
- Day 85–364 · 1.7 mg 1.7 mg of each, one step from the top
- Day 113+ · 2.4 mg 2.4 mg/2.4 mg, the maintenance dose

[Every card for CagriSema, with its sources](https://pepvault.app/peptides/cagrisema#weeks)

### Amycretin

- Day 1–28 A very low start
- Day 57–140 · 1.25 mg The lowest dose tested for weight
- Day 85–252 With type 2 diabetes
- Day 113–196 · 5 mg Five milligrams
- Day 169–252 · 20 mg Twenty milligrams
- Day 253+ A long-term medicine, not a course

[Every card for amycretin, with its sources](https://pepvault.app/peptides/amycretin#weeks)

## With this comparison

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Amycretin

- [Amycretin: the full reference](https://pepvault.app/peptides/amycretin)
- [Amycretin dose guide](https://pepvault.app/lab/dosage/amycretin)

### Mixing charts

- [Amycretin 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/amycretin-10mg)

### Studies

- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 4 studies](https://pepvault.app/research#cagrisema)
- [Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeks](https://pepvault.app/research/amycretin-mora-2026)
- [Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetes](https://pepvault.app/research/amycretin-mora-2026-42532080)
- [Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trial](https://pepvault.app/research/amycretin-dahl-2025)
- [All 6 studies](https://pepvault.app/research#amycretin)

### Compared with

- [CagriSema vs Semaglutide](https://pepvault.app/peptides/compare/cagrisema-vs-semaglutide)
- [CagriSema vs Tirzepatide](https://pepvault.app/peptides/compare/cagrisema-vs-tirzepatide)
- [Semaglutide vs Amycretin](https://pepvault.app/peptides/compare/semaglutide-vs-amycretin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Amylin analogue](https://pepvault.app/glossary/amylin-analogue)

## Questions people ask

### How long do CagriSema and amycretin last?

The half-life of CagriSema is ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial). The half-life of amycretin is ~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026).

### How often are CagriSema and amycretin taken?

CagriSema: weekly. Route: SubQ injection. Amycretin: weekly. Route: SubQ injection.

### How are CagriSema and amycretin dosed in research?

The research range for CagriSema is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for amycretin is 0.4–60 mg, with a 0.2 mg starting dose. Studied in research — not a recommendation.

### What are the common side effects of CagriSema and amycretin?

For CagriSema, the library lists: nausea, vomiting, diarrhea, constipation, abdominal pain. For amycretin: nausea, vomiting, diarrhea, decreased appetite.

## Each one in full

- [CagriSema: dosage, half-life & reference guide](https://pepvault.app/peptides/cagrisema)
- [Amycretin: dosage, half-life & reference guide](https://pepvault.app/peptides/amycretin)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)
- [Amycretin dose guide](https://pepvault.app/lab/dosage/amycretin)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking CagriSema or amycretin? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking CagriSema or amycretin? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this comparison

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Amycretin

- [Amycretin: the full reference](https://pepvault.app/peptides/amycretin)
- [Amycretin dose guide](https://pepvault.app/lab/dosage/amycretin)

### Mixing charts

- [Amycretin 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/amycretin-10mg)

### Studies

- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 4 studies](https://pepvault.app/research#cagrisema)
- [Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeks](https://pepvault.app/research/amycretin-mora-2026)
- [Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetes](https://pepvault.app/research/amycretin-mora-2026-42532080)
- [Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trial](https://pepvault.app/research/amycretin-dahl-2025)
- [All 6 studies](https://pepvault.app/research#amycretin)

### Compared with

- [CagriSema vs Semaglutide](https://pepvault.app/peptides/compare/cagrisema-vs-semaglutide)
- [CagriSema vs Tirzepatide](https://pepvault.app/peptides/compare/cagrisema-vs-tirzepatide)
- [Semaglutide vs Amycretin](https://pepvault.app/peptides/compare/semaglutide-vs-amycretin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Amylin analogue](https://pepvault.app/glossary/amylin-analogue)

<!--promo-->

PepVault for iPhone

## Taking CagriSema or amycretin? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [CagriSema vs Semaglutide](https://pepvault.app/peptides/compare/cagrisema-vs-semaglutide)
- [CagriSema vs Tirzepatide](https://pepvault.app/peptides/compare/cagrisema-vs-tirzepatide)
- [Semaglutide vs Amycretin](https://pepvault.app/peptides/compare/semaglutide-vs-amycretin)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Metabolic & GLP-1 peptides](https://pepvault.app/peptides#metabolic)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
